Menu
Close

'The FDA has granted the moxetumomab pasudotox BLA Priority Review status

lse:azn

#1

AstraZeneca’s global biologics research arm MedImmune announced Tuesday that the US Food and Drug Administration has accepted the Biologics License Application for moxetumomab pasudotox, a potential new medicine for the treatment of adult patients with hairy cell leukaemia. ‘The FDA has granted the moxetumomab pasudotox BLA Priority Review status with a Prescription Drug User Fee Act date set for the third quarter of 2018,’ the firm said. Moxetumomab pasudotox is an investigational anti-CD22 recombinant immunotoxin and a potential new medicine for the treatment of adult patients with hairy cell leukaemia who have received at least two prior lines of therapy. Story provided by StockMarketWire.com